Grufity logo
Grufity logo

Latest Lion Point Capital, LP Stock Portfolio

$16.73Million– No. of Holdings #35

Lion Point Capital, LP Performance:
2026 Q1: -10.87%YTD: -10.87%2025: 17.04%
Performance for 2026 Q1 is -10.87%, and YTD is -10.87%, and 2025 is 17.04%.

About Lion Point Capital, LP and 13F Hedge Fund Stock Holdings

On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Lion Point Capital, LP reported an equity portfolio of $16.7 Millions as of 31 Mar, 2026.

The top stock holdings of Lion Point Capital, LP are PRAX, MLTX, RPRX. The fund has invested 8.6% of it's portfolio in PRAXIS PRECISION MEDICINES I and 7.5% of portfolio in MOONLAKE IMMUNOTHERAPEUTICS.

The fund managers got completely rid off DAY ONE BIOPHARMACEUTICALS I (DAWN), VENTYX BIOSCIENCES INC (VTYX) and MINERVA NEUROSCIENCES INC (NERV) stocks. The fund showed a lot of confidence in some stocks as they added substantially to COMPASS PATHWAYS PLC (CMPS), HUMACYTE INC (HUMA) and MILESTONE PHARMACEUTICALS IN (MIST).
Lion Point Capital, LP Equity Portfolio Value
Last Reported on: 15 May, 2026

Lion Point Capital, LP Annual Return Estimates Vs S&P 500

Our best estimate is that Lion Point Capital, LP made a return of -10.87% in the last quarter. In trailing 12 months, it's portfolio return was 27.97%.
  • Performance
  • S&P 500

New Buys

No new stocks were added by Lion Point Capital, LP

Additions

Ticker% Inc.
compass pathways plc37.93
humacyte inc30.00
milestone pharmaceuticals in8.61
Additions to existing portfolio by Lion Point Capital, LP

Reductions

None of the existing positions were reduced by Lion Point Capital, LP

Sold off

Ticker$ Sold
day one biopharmaceuticals i-391,440
ventyx biosciences inc-374,745
minerva neurosciences inc-140,700
mersana therapeutics inc-2,893
Lion Point Capital, LP got rid off the above stocks

Sector Distribution

Lion Point Capital, LP has about 91.1% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare91.1
Others8.9

Market Cap. Distribution

Lion Point Capital, LP has about 10.6% of it's portfolio invested in the large-cap and mega-cap stocks.

  • SMALL-CAP
  • MID-CAP
  • MICRO-CAP
  • LARGE-CAP
  • UNALLOCATED
  • NANO-CAP
Category%
SMALL-CAP45.2
MID-CAP15.5
MICRO-CAP14.4
LARGE-CAP10.6
UNALLOCATED8.9
NANO-CAP5.5

Stocks belong to which Index?

About 47.2% of the stocks held by Lion Point Capital, LP either belong to S&P 500 or RUSSELL 2000 index.

  • Others
  • RUSSELL 2000
  • S&P 500
Index%
Others52.7
RUSSELL 200045
S&P 5002.2
Top 5 Winners (%)%
MLTX
moonlake immunotherapeutics
41.4 %
EWTX
edgewise therapeutics inc
26.9 %
RPRX
royalty pharma plc
24.1 %
INVA
innoviva inc
16.6 %
LNTH
lantheus hldgs inc
14.0 %
Top 5 Winners ($)$
MLTX
moonlake immunotherapeutics
0.4 M
RPRX
royalty pharma plc
0.2 M
PRAX
praxis precision medicines i
0.1 M
GERN
geron corp
0.1 M
SNDX
syndax pharmaceuticals inc
0.1 M
Top 5 Losers (%)%
JSPR
jasper therapeutics inc
-52.1 %
RGNX
regenxbio inc
-41.8 %
MCRB
seres therapeutics inc
-40.4 %
MIST
milestone pharmaceuticals in
-40.1 %
AZTA
azenta inc
-36.5 %
Top 5 Losers ($)$
MIST
milestone pharmaceuticals in
-0.7 M
JSPR
jasper therapeutics inc
-0.4 M
HUMA
humacyte inc
-0.2 M
MCRB
seres therapeutics inc
-0.2 M
BNTC
benitec biopharma inc
-0.2 M

Lion Point Capital, LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Lion Point Capital, LP

Lion Point Capital, LP has 35 stocks in it's portfolio. About 54.6% of the portfolio is in top 10 stocks. MIST proved to be the most loss making stock for the portfolio. MLTX was the most profitable stock for Lion Point Capital, LP last quarter.

Last Reported on: 15 May, 2026
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions